Epigral Incorporates Wholly Owned Subsidiary, 'Epigral Advanced Materials Limited'

Epigral Limited announced on July 7, 2026 that it has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited. The new entity, formed to manufacture chemicals, marks a concrete step toward the “new chemistry” platform management has been working on, though the company did not disclose any specific product, capital commitment, or timeline for the venture.

About Epigral

The Strategic Context: A New Chemistry Platform Takes Shape

In the May 2026 earnings call, Milind Kotecha (Investor Relations & Strategy) confirmed:
> “We are working on the new chemistry for further expansion. That is under process with the management and once it is freezed, we will be announcing that, maybe in a couple of months.”

Earlier, in the August 2025 call, Chairman Maulik Patel gave a clear sense of the project’s distinct nature:
> “It is going to be completely different. It is not going to depend on our existing customers or existing site, no. It is going to be completely different value chain.”

He also described it as an “import substitution product where demand is expected to grow in double‑digit percentage for next 10 years or so, and we can generate good ROCE.”

The new chemistries are being developed for a separate 100‑acre land parcel in Dahej, away from the existing integrated complex. That geographic separation reinforces the logic of a distinct legal structure . Notably, the parent’s own annual report argues that Epigral’s core advantage lies in a fully integrated complex — which makes the decision to house a brand‑new chain in a separate subsidiary a deliberate strategic choice, likely aimed at ring‑fencing risk and allowing a focused capital structure .

What We Don’t Know

- Specific products: The term “advanced materials” has not been used by management before. The closest hints come from the R&D centre’s work on “further molecules for Chlorotoluene and other new molecules,” described as intermediates for pharmaceuticals and agrochemicals .
- Capital plan: The subsidiary’s initial capital is only a token. The parent’s ongoing capex — doubling CPVC and epichlorohydrin capacity — is expected to consume about ₹400 crore each in FY27 and FY28 . Any material investment in the new venture would require separate board approval and disclosure.
- Technology partners: No licensing, technical collaboration, or strategic partnership for the advanced‑materials foray has been disclosed. The annual report explicitly states “NA” for imported technology over the past three years .
- Timeline: Management has said the new project is meant to drive growth from FY29 onward, with a typical setup time of two years, but no commissioning target has been given for the subsidiary .

Management has indicated that an announcement on the new project is expected “this year” — likely before the end of calendar 2026 . Until then, the subsidiary remains a signal of intent rather than a defined business.

---

Sources

1 Financial statement analysis
2 Earnings-call transcript, May 2026
3 Investor presentation, May 2026
4 Earnings-call transcript, Feb 2026
5 Earnings-call transcript, Nov 2025
6 Investor presentation, Nov 2025
7 Earnings-call transcript, Aug 2025
8 Annual report, May 2026
9 Investor presentation, Jan 2026
10 Announcement under Regulation 30 (LODR)-Acquisition
11 BSE/NSE EOD prices & index levels